US equities
|
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Foghorn Therapeutics Inc. - Common Stock
(NQ:
FHTX
)
2.000
-0.010 (-0.50%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Foghorn Therapeutics Inc. - Common Stock
< Previous
1
2
3
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
October 20, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
October 13, 2026
From
Pomerantz LLP
Via
GlobeNewswire
FHTX Investors with $100,000 in Losses Have Opportunity to Join Foghorn Therapeutics Inc. Fraud Investigation with SBS Law
October 11, 2026
From
Schall, Brown & Schwartz LLP
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
October 06, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
October 01, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update
August 06, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies
June 22, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
June 22, 2026
Via
Investor Brand Network
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
June 05, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
May 12, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
May 07, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
April 21, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
April 09, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
March 11, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
February 24, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
February 23, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
February 03, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
January 13, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
January 09, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
November 25, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
November 05, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
November 03, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
October 30, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
October 16, 2025
Foghorn to host a virtual investor event on updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs on Thursday October 30, 2025, at 12 p.m. EDT
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
August 27, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
August 05, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
May 22, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
May 14, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
May 05, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
May 01, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
